


DS86760016

Cat. No.:	HY-124679
CAS No.:	1853176-89-2
Molecular Formula:	C ₉ H ₁₁ BClNO ₄
Molecular Weight:	243.45
Target:	Bacterial
Pathway:	Anti-infection
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	DS86760016 is a potent leucyl-tRNA synthetase (LeuRS) inhibitor with activity against multidrug-resistant (MDR) Gram-negative bacteria, such as <i>Escherichia coli</i> , <i>Klebsiella pneumoniae</i> , and <i>Pseudomonas aeruginosa</i> . DS86760016 inhibits LeuRS enzymes from <i>Escherichia coli</i> , <i>Pseudomonas aeruginosa</i> , and <i>Acinetobacter baumannii</i> , with IC ₅₀ s of 0.38, 0.62, and 0.16 μM, respectively ^{[1][2]} .
In Vitro	DS86760016 inhibits some Gram-negative bacteria with MICs ranging from 0.25 to 2 μg/ml. The MIC of DS86760016 against Gram-positive bacteria is >32 μg/ml. DS86760016 is active against both susceptible and these MDR <i>P. aeruginosa</i> , <i>E. coli</i> , and <i>K. pneumoniae</i> strains, with an MIC ₉₀ of 2 μg/ml ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo	DS86760016 (7.5-220 mg/kg; s.c.; q6h for 7 days) shows moderate spontaneous resistance (FSR) ^[1] . The pharmacokinetic (PK) parameters of DS86760016 in mouse, rat, monkey, and dog plasma by the intravenous (i.v.) route are test. DS86760016 shows lower intravenous plasma clearances (CL _p) of 11, 29, 5.6, and 4.5 ml/min/kg in mouse, rat, monkey, and dog plasma, respectively. The plasma half-lives (t _{1/2}) for DS86760016 are 1.9, 1.5, 8.6, and 8.3 h in mice, rats, monkeys, and dogs, respectively. The lower plasma clearance resulted in higher plasma exposures for DS86760016, with dose-normalized areas under the curve after i.v. administration (DNAUC _{IVS}) of 1.5, 0.6, 3.7, and 3.0 μg h kg/ml/mg in mice, rats, monkeys, and dogs, respectively ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Model:	Immunocompetent female Swiss Webster mice (urinary tract infection, UTI model) ^[1]
Dosage:	7.5, 30, 220 mg/kg
Administration:	S.c.; q6h for 7 days
Result:	Bacteria resistant to DS86760016 were detected in a few animals after 1 day of treatment at doses of 7.5 and 30 mg/kg q6h; however, no resistant bacteria were detected at these doses after 7 days of treatment. No resistance was observed in any of the mice treated at a dose of 220 mg/kg q6h.

REFERENCES

[1]. Purnapatre KP, et al. In Vitro and In Vivo Activities of DS86760016, a Novel Leucyl-tRNA Synthetase Inhibitor for Gram-Negative Pathogens. *Antimicrob Agents Chemother.* 2018;62(4):e01987-17. Published 2018 Mar 27.

[2]. Kumar M, et al. DS86760016, a Leucyl-tRNA Synthetase Inhibitor with Activity against *Pseudomonas aeruginosa*. *Antimicrob Agents Chemother.* 2019;63(4):e02122-18. Published 2019 Mar 27.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA